14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RAPT vs ABCL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). RAPT carries a Unified Composite Score of 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin), whereas ABCL carries 63.3/100 (BUY) at $11.14 (27.6x Forward P/E, -1550.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPT vs ABCL. Trailing 12-month operating profitability (RAPT 0.0% vs ABCL -1550.0%) and valuation multiples (RAPT N/M vs ABCL 27.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.8B market capitalization and -1550.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RAPT vs ABCL Key Questions & Quantitative Answers
As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). RAPT carries a Unified Composite Score of 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin), whereas ABCL carries 63.3/100 (BUY) at $11.14 (27.6x Forward P/E, -1550.0% operating margin). Technically, RAPT sits in a Markup phase (RSI 79.7, UNCLASSIFIED options structure) and ABCL sits in a Neutral phase (RSI 43.3, CONSOLIDATION options structure).
ABCL leads the Growth & Scale pillar: RAPT posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ABCL at -76.3% YoY revenue growth and +45.9% YoY earnings growth on $66M TTM revenue (N/A gross margin, -1550.0% operating margin). On trailing 12-month operating scale, RAPT generates N/A in USD-normalized revenue versus $66M for ABCL. In operating R&D and SG&A reinvestment, RAPT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABCL.
ABCL screens cheaper on headline valuation multiples. RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 56.9x EV/Revenue (-49.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAPT (-85.4% ROE) versus ABCL (-17.3% ROE) capital efficiency.
In options market volatility and institutional positioning, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk). By comparison, ABCL carries 80.8% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.30β · 87% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.